Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2021-09-14 15:46:10 UTC |
---|
HMDB ID | HMDB0000273 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Thymidine |
---|
Description | Thymidine, also known as deoxythymidine or deoxyribosylthymine or thymine deoxyriboside, is a pyrimidine deoxynucleoside. It consists of the nucleobase thymine attached to deoxyribose through a beta N- glycosidic bond. Thymidine also belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. Pyrimidine 2'-deoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2. Deoxythymidine (or thymidine) is the DNA nucleoside T, which pairs with deoxyadenosine (A) in double-stranded DNA. Therefore, thymidine is essential to all life. Indeed, thymidine exists in all living species, ranging from bacteria to plants to humans. Within humans, thymidine participates in a number of enzymatic reactions. In particular, thymidine can be biosynthesized from 5-thymidylic acid through its interaction with the enzyme cytosolic purine 5'-nucleotidase. In addition, thymidine can be converted into 5-thymidylic acid; which is catalyzed by the enzyme thymidine kinase. Deoxythymidine can be phosphorylated with one, two or three phosphoric acid groups, creating dTMP (deoxythymidine monophosphate), dTDP, or dTTP (for the di- and tri- phosphates, respectively). dTMP can be incorporated into DNA via DNA polymerases. In cell biology, thymidine can be used to synchronize the cells in S phase. Derivatives of thymidine are used in a number of drugs, including Azidothymidine (AZT), which is used in the treatment of HIV infection. AZT inhibits the process of reverse transcription in the human immunodeficiency virus. |
---|
Structure | CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1 |
---|
Synonyms | Value | Source |
---|
1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | ChEBI | 2'-Deoxy-5-methyluridine | ChEBI | 2'-Deoxythymidine | ChEBI | 2'-Thymidine | ChEBI | 5-Methyl-2'-deoxyuridine | ChEBI | Deoxythymidine | ChEBI | DTHD | ChEBI | T | ChEBI | Thymine 2'-deoxyriboside | ChEBI | 1-(2-Deoxy-b-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | Generator | 1-(2-Deoxy-β-D-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | Generator | 1-(2-Deoxy-b-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione | HMDB | 1-(2-Deoxy-beta-delta-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione | HMDB | 1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione | HMDB | 2'-Deoxy-5-methyl-uridine | HMDB | 5-Methyldeoxyuridine | HMDB | Deoxyribothymidine | HMDB | DT | HMDB | DThyd | HMDB | Thymidin | HMDB | Thymine 2-desoxyriboside | HMDB | Thymine deoxyriboside | HMDB | Thymine-1 2-deoxy-b-D-ribofuranoside | HMDB | Thymine-1 2-deoxy-beta-delta-ribofuranoside | HMDB | 2' Deoxythymidine | HMDB |
|
---|
Chemical Formula | C10H14N2O5 |
---|
Average Molecular Weight | 242.2286 |
---|
Monoisotopic Molecular Weight | 242.090271568 |
---|
IUPAC Name | 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
---|
Traditional Name | thymidine |
---|
CAS Registry Number | 50-89-5 |
---|
SMILES | CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O |
---|
InChI Identifier | InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1 |
---|
InChI Key | IQFYYKKMVGJFEH-XLPZGREQSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. Pyrimidine 2'-deoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Pyrimidine nucleosides |
---|
Sub Class | Pyrimidine 2'-deoxyribonucleosides |
---|
Direct Parent | Pyrimidine 2'-deoxyribonucleosides |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidine 2'-deoxyribonucleoside
- Pyrimidone
- Hydroxypyrimidine
- Hydropyrimidine
- Pyrimidine
- Heteroaromatic compound
- Tetrahydrofuran
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 73.5 mg/mL | Not Available | LogP | -0.93 | SANGSTER (1993) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Thymidine,1TMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO)O2)C(=O)[NH]C1=O | 2332.5 | Semi standard non polar | 33892256 | Thymidine,1TMS,isomer #2 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C)O2)C(=O)[NH]C1=O | 2281.7 | Semi standard non polar | 33892256 | Thymidine,1TMS,isomer #3 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)N([Si](C)(C)C)C1=O | 2342.1 | Semi standard non polar | 33892256 | Thymidine,2TMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C(=O)[NH]C1=O | 2312.0 | Semi standard non polar | 33892256 | Thymidine,2TMS,isomer #2 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO)O2)C(=O)N([Si](C)(C)C)C1=O | 2397.2 | Semi standard non polar | 33892256 | Thymidine,2TMS,isomer #3 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2384.3 | Semi standard non polar | 33892256 | Thymidine,3TMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2403.0 | Semi standard non polar | 33892256 | Thymidine,3TMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2498.5 | Standard non polar | 33892256 | Thymidine,3TMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C)[C@@H](CO[Si](C)(C)C)O2)C(=O)N([Si](C)(C)C)C1=O | 2732.2 | Standard polar | 33892256 | Thymidine,1TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO)O2)C(=O)[NH]C1=O | 2576.3 | Semi standard non polar | 33892256 | Thymidine,1TBDMS,isomer #2 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)[NH]C1=O | 2550.0 | Semi standard non polar | 33892256 | Thymidine,1TBDMS,isomer #3 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2574.8 | Semi standard non polar | 33892256 | Thymidine,2TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)[NH]C1=O | 2796.1 | Semi standard non polar | 33892256 | Thymidine,2TBDMS,isomer #2 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2843.8 | Semi standard non polar | 33892256 | Thymidine,2TBDMS,isomer #3 | CC1=CN([C@H]2C[C@H](O)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2815.4 | Semi standard non polar | 33892256 | Thymidine,3TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 3049.2 | Semi standard non polar | 33892256 | Thymidine,3TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 3118.0 | Standard non polar | 33892256 | Thymidine,3TBDMS,isomer #1 | CC1=CN([C@H]2C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O2)C(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2994.0 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Thymidine GC-MS (2 TMS) | splash10-0udi-1900000000-8e769118bc877facb05f | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-MS (3 TMS) | splash10-0ue9-2910000000-823bcee487948a9c786f | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-MS (Non-derivatized) | splash10-0udi-1900000000-8e769118bc877facb05f | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-MS (Non-derivatized) | splash10-0ue9-2910000000-823bcee487948a9c786f | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-EI-TOF (Non-derivatized) | splash10-0udi-0900000000-996530d1ea081ac2a7c7 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-EI-TOF (Non-derivatized) | splash10-0l6r-0900000000-4645a52830204c8ef5d0 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Thymidine GC-EI-TOF (Non-derivatized) | splash10-0zfr-0900000000-76b8a050c10b514ed50b | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-9530000000-627a60bbe3e0b90f58cb | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (2 TMS) - 70eV, Positive | splash10-0g4i-7905000000-7b0c67709e3a5f91841a | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Thymidine GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-01dj-9300000000-6e24b5b6d36e07dd73d0 | 2018-05-25 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-004i-0900000000-1c2ba2f2aace4a76cdea | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-004i-3900000000-d177672ef3f383adbb5d | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-01p9-9000000000-4483af567feecb34a651 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-0006-0090000000-435be9f03e969dbabb79 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-0006-5690000000-79b230d52929aa67bbf2 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-0006-9100000000-28a604508965067c85c5 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-0006-9000000000-360e0667ff3d7d77e706 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-0006-9000000000-b1fecd2d1fa166e22d5f | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive-QTOF | splash10-004i-1920000000-1a2e609b8a19ef491964 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive-QTOF | splash10-004i-1900000000-5e4a733641fa285e7f74 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive-QTOF | splash10-004i-3900000000-f734d5813fecb7a31814 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive-QTOF | splash10-01t9-5900000000-53b0016c66aa014c2abc | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive-QTOF | splash10-03e9-9600000000-48f1a0d5512651a93e14 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-004i-1910000000-f02c2133ea475f4f838c | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-08i0-2900000000-ec21970768da0fbf8ce5 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-0002-9000000000-17c234cb0e8de5ae82f4 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-014i-9000000000-d7e5ed251a93758682ec | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ , negative-QTOF | splash10-0006-0090000000-435be9f03e969dbabb79 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Thymidine LC-ESI-QQ , negative-QTOF | splash10-0006-5690000000-79b230d52929aa67bbf2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 10V, Positive-QTOF | splash10-004i-0900000000-9ad72ff6cb2e2dfab911 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 20V, Positive-QTOF | splash10-004i-4900000000-3b1e6c50c2450e123648 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 40V, Positive-QTOF | splash10-004i-6900000000-d30b05dfe1b6d25ebd2b | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 10V, Negative-QTOF | splash10-052g-1940000000-ce16baa1ceb8a83565c2 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 20V, Negative-QTOF | splash10-0ufr-3920000000-c6ff3f238b6fed007635 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Thymidine 40V, Negative-QTOF | splash10-0006-9200000000-104a4f5a4fe8a0ed5ca3 | 2016-09-12 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Extracellular
- Mitochondria
- Lysosome
|
---|
Biospecimen Locations | - Amniotic Fluid
- Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Urine
|
---|
Tissue Locations | - Adipose Tissue
- Adrenal Gland
- Bladder
- Epidermis
- Fibroblasts
- Intestine
- Kidney
- Neuron
- Pancreas
- Placenta
- Platelet
- Prostate
- Skeletal Muscle
- Spleen
- Testis
- Thyroid Gland
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Amniotic Fluid | Detected and Quantified | 1.52 +/- 1.21 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.2 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.21 +/- 0.13 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | <0.1 uM | Adult (>18 years old) | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.221 +/- 0.800 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 2.52 +/- 0.579 uM | Adult (>18 years old) | Female | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0-3 umol/mmol creatinine | Children (1 - 18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 2.113 +/- 0.875 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 2.46 +/- 2.03 umol/mmol creatinine | Children (1-13 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1.38 +/- 1.02 umol/mmol creatinine | Adolescent (13-18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 6.87 +/- 4.86 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 2.2 (0.7-3.9) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <0.1 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected and Quantified | <5 umol/mmol creatinine | Adult (>18 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.31 +/- 0.09 uM | Adult (>18 years old) | Both | Canavan disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.06 (0.0-0.120 uM | Adult (>18 years old) | Both | Degenerative disc disease | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Attachment loss | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Missing teeth | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Periodontal Probing Depth | | details | Urine | Detected and Quantified | 3.431 +/- 0.539 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details | Urine | Detected and Quantified | 4.58 +/- 4.58 umol/mmol creatinine | Adult (>18 years old) | Both | Canavan disease | | details | Urine | Detected and Quantified | 29 umol/mmol creatinine | Adult (>18 years old) | Male | Thymidine phosphorylase deficiency | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Canavan disease |
---|
- Tavazzi B, Lazzarino G, Leone P, Amorini AM, Bellia F, Janson CG, Di Pietro V, Ceccarelli L, Donzelli S, Francis JS, Giardina B: Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. Clin Biochem. 2005 Nov;38(11):997-1008. Epub 2005 Sep 1. [PubMed:16139832 ]
| Degenerative disc disease |
---|
- Eells JT, Spector R: Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res. 1983 Nov;8(11):1451-7. [PubMed:6656991 ]
| Colorectal cancer |
---|
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Attachment loss |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Missing teeth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Periodontal Probing Depth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
| Thymidine phosphorylase deficiency |
---|
- Bakker JA, Schlesser P, Smeets HJ, Francois B, Bierau J: Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome. J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S139-43. doi: 10.1007/s10545-010-9049-y. Epub 2010 Feb 12. [PubMed:20151198 ]
|
|
---|
Associated OMIM IDs | - 271900 (Canavan disease)
- 114500 (Colorectal cancer)
- 610247 (Eosinophilic esophagitis)
- 603041 (Thymidine phosphorylase deficiency)
|
---|
External Links |
---|
DrugBank ID | DB04485 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB031201 |
---|
KNApSAcK ID | C00019698 |
---|
Chemspider ID | 5585 |
---|
KEGG Compound ID | C00214 |
---|
BioCyc ID | THYMIDINE |
---|
BiGG ID | 50348 |
---|
Wikipedia Link | Thymidine |
---|
METLIN ID | 3375 |
---|
PubChem Compound | 5789 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 17748 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | THYMD |
---|
MarkerDB ID | MDB00000132 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Herdewijn, P.; Kerremans, L.; Wigerinck, P.; Vandendriessche, F.; Van Aerschot, A. Synthesis of thymidine from 5-iodo-2'-deoxyuridine. Tetrahedron Letters (1991), 32(34), 4397-400. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Eells JT, Spector R: Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res. 1983 Nov;8(11):1451-7. [PubMed:6656991 ]
- Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID: Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res. 2005 Feb 1;11(3):1294-301. [PubMed:15709201 ]
- Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G: Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. J Clin Oncol. 1999 Sep;17(9):2922-31. [PubMed:10561372 ]
- Vogel W, Schempp W, Sigwarth I: Comparison of thymidine, fluorodeoxyuridine, hydroxyurea, and methotrexate blocking at the G1/S phase transition of the cell cycle, studied by replication patterns. Hum Genet. 1978 Dec 18;45(2):193-8. [PubMed:153886 ]
- Schill WB, Miska W: Possible effects of the kallikrein-kinin system on male reproductive functions. Andrologia. 1992 Mar-Apr;24(2):69-75. [PubMed:1318646 ]
- Grinlinton FM, Skinner MA, Birchall NM, Tan PL: Gamma delta + T cells from patients with psoriatic and rheumatoid arthritis respond to streptococcal antigen. J Rheumatol. 1993 Jun;20(6):982-7. [PubMed:8350335 ]
- Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ: Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1107-15. [PubMed:15234045 ]
- Isoda K, Kim H, Hamamoto Y: A study on the mesothelial cell kinetics in pleural effusions by DNA cytophotometry and autoradiography with tritiated thymidine. Acta Pathol Jpn. 1984 Jul;34(4):775-83. [PubMed:6485796 ]
- Ashkenazi S, Cleary KR, Pickering LK, Murray BE, Cleary TG: The association of Shiga toxin and other cytotoxins with the neurologic manifestations of shigellosis. J Infect Dis. 1990 May;161(5):961-5. [PubMed:2324546 ]
- Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D: Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983 Mar;1(3):208-16. [PubMed:6607976 ]
- Svendsen LB, Stener Jorgensen F, Hart Hansen O, Johansen A, Horn T, Larsen JK: Influence of the prostaglandin E1 analogue Rioprostil on the human gastric mucosa. Digestion. 1987;37(1):29-34. [PubMed:3111919 ]
|
---|